Evidence map›Paper›PMID 36384804›Full record

ArticleRadiation oncology (London, England)2022

Dummy run quality assurance study in the Korean Radiation Oncology Group 19 - 09 multi-institutional prospective cohort study of breast cancer.

Myeongsoo Kim, Boram Park, Haksoo Kim, Yeon-Joo Kim, Dong Ju Choi, Weonkuu Chung, Yeon Joo Kim, Hyun Soo Shin, Jung Ho Im, Chang-Ok Suh and 13 more

Abstract read
In one paragraph

Article in Radiation oncology (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Myeongsoo Kim *Department of Radiation Oncology, National Cancer Center, Goyang, Korea.
Boram Park *Biomedical Statistics Center, Samsung Medical Center, Seoul, Korea.
Haksoo KimDepartment of Radiation Oncology, National Cancer Center, Goyang, Korea. haksoo.kim@ncc.re.kr.
Yeon-Joo KimDepartment of Radiation Oncology, National Cancer Center, Goyang, Korea. yjkim1785@ncc.re.kr.
Dong Ju ChoiDepartment of Radiation Oncology, National Cancer Center, Goyang, Korea.
Weonkuu ChungRadiation Oncology Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea.
Yeon Joo KimDepartment of Radiation Oncology, Kangwon National University Hospital, Chuncheon, Korea.
Hyun Soo ShinDepartment of Radiation Oncology, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Jung Ho ImDepartment of Radiation Oncology, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Chang-Ok SuhDepartment of Radiation Oncology, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Jin Hee KimDepartment of Radiation Oncology, Keimyung University Dongsan Medical Center, Daegu, Korea.
Boram HaDepartment of Radiation Oncology, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea.
Mi Young KimDepartment of Radiation Oncology, Kyungpook National University Chilgok Hospital, Daegu, Korea.
Jongmoo ParkDepartment of Radiation Oncology, School of Medicine, Kyungpook National University, Daegu, Korea.
Jeongshim LeeDepartment of Radiation Oncology, Inha University Hospital, Incheon, Korea.
Sung-Ja AhnDepartment of Radiation Oncology, Chonnam National University Hwasun Hospital, Jeollanam-do, Gwangju, Korea.
Sun Young LeeDepartment of Radiation Oncology, Jeonbuk National University Hospital, Jeonju, Korea.
Grace KusumawidjajaDivision of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore.
Faye LimDivision of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore.
Won Kyung ChoDepartment of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Haeyoung KimDepartment of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Doo Ho ChoiDepartment of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Won ParkDepartment of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Funding

National Cancer Center Korea 2110210
6 · The paper itself

Abstract

backgroundThe Korean Radiation Oncology Group (KROG) 19 - 09 prospective cohort study aims to determine the effect of regional nodal irradiation on regional recurrence rates in ypN0 breast cancer patients. Dosimetric variations between radiotherapy (RT) plans of participating institutions may affect the clinical outcome of the study. We performed this study to assess inter-institutional dosimetric variations by dummy run.

methodsTwelve participating institutions created RT plans for four clinical scenarios using computed tomography images of two dummy cases. Based on a reference structure set, we analyzed dose-volume histograms after collecting the RT plans.

resultsWe found variations in dose distribution between institutions, especially in the regional nodal areas. Whole breast and regional nodal irradiation (WBI + RNI) plans had lower inter-institutional agreement and similarity for 95% isodose lines than WBI plans. Fleiss's kappa values, which were used to measure inter-institutional agreement for the 95% isodose lines, were 0.830 and 0.767 for the large and medium breast WBI plans, respectively, and 0.731 and 0.679 for the large and medium breast WBI + RNI plans, respectively. There were outliers in minimum dose delivered to 95% of the structure (D95%) of axillary level 1 among WBI plans and in D95% of the interpectoral region and axillary level 4 among WBI + RNI plans.

conclusionWe found inter-institutional and inter-case variations in radiation dose delivered to target volumes and organs at risk. As KROG 19 - 09 is a prospective cohort study, we accepted the dosimetric variation among the different institutions. Actual patient RT plan data should be collected to achieve reliable KROG 19 - 09 study results.

Indexed as

Breast NeoplasmsAxillaFemaleHumansProspective StudiesRadiotherapy, AdjuvantRepublic of KoreaBreast neoplasmsDosimetric variationsDummy runQuality assuranceRadiotherapy

Identifiers

PMID36384804
PMCPMC9670516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.